In a proof-of-principle study, De Mattos-Arruda et al. subjected primary tumor, lung metastasis, and plasma samples from a metastatic ER+/HER2− breast cancer patient to massively parallel sequencing targeting 300 genes that are frequently mutated in cancer [91]. The gene discussed is ESR1; the disease is breast cancer.